Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease

(2014) D. T. Rubin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy

(2014) Raquel Franco Leal et al.   GUT

Adverse events in IBD: to stop or continue immune suppressant and biologic treatment

(2014) Leon P McLean et al.   Expert Review of Gastroenterology & Hepatology

Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Antagonizing the  4 1 Integrin, but Not  4 7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis

(2013) K. G. Haanstra et al.   JOURNAL OF IMMUNOLOGY

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

(2013) Catherine Milch et al.   JOURNAL OF NEUROIMMUNOLOGY

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

(2012) Eric R. Fedyk et al.   INFLAMMATORY BOWEL DISEASES

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Review: Optimal use of biologics in the management of Crohn’s disease

(2010) Remo Panaccione et al.   Therapeutic Advances in Gastroenterology

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

(2008) William J. Sandborn   GASTROENTEROLOGY